ProQR Therapeutics Management
Management criteria checks 4/4
ProQR Therapeutics' CEO is Daniel de Boer, appointed in Feb 2012, has a tenure of 13.25 years. total yearly compensation is €1.83M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $1.11M. The average tenure of the management team and the board of directors is 5.3 years and 7 years respectively.
Key information
Daniel de Boer
Chief executive officer
€1.8m
Total compensation
| CEO salary percentage | 29.8% |
| CEO tenure | 13.3yrs |
| CEO ownership | 0.7% |
| Management average tenure | 5.3yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%
Apr 14
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding
Dec 14There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €2m | €545k | -€28m |
| Sep 30 2024 | n/a | n/a | -€24m |
| Jun 30 2024 | n/a | n/a | -€22m |
| Mar 31 2024 | n/a | n/a | -€27m |
| Dec 31 2023 | €2m | €524k | -€28m |
| Sep 30 2023 | n/a | n/a | -€36m |
| Jun 30 2023 | n/a | n/a | -€54m |
| Mar 31 2023 | n/a | n/a | -€59m |
| Dec 31 2022 | €2m | €504k | -€64m |
| Sep 30 2022 | n/a | n/a | -€69m |
| Jun 30 2022 | n/a | n/a | -€61m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€61m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
Compensation vs Market: Daniel's total compensation ($USD2.07M) is about average for companies of similar size in the US market ($USD1.81M).
Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.
CEO
Daniel de Boer (41 yo)
13.3yrs
Tenure
€1,830,000
Compensation
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 13.3yrs | €1.83m | 0.67% $ 1.1m | |
| Co-Founder | 13.3yrs | €488.00k | 0.78% $ 1.3m | |
| Founder & Independent Member of Supervisory Board | no data | €107.00k | 0.40% $ 660.5k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief People & Operations Officer | 5.3yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Junior Financial Controller | no data | no data | no data |
5.3yrs
Average Tenure
48yo
Average Age
Experienced Management: PRQR's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Member of Supervisory Board | 11.3yrs | €107.00k | 0.40% $ 660.5k | |
| Independent Member of Supervisory Board | 10.7yrs | €99.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Supervisory Board Member | 2yrs | €175.00k | 0.036% $ 58.9k | |
| Independent Chairman of Supervisory Board & Chairman of Scientific Advisory Board | 8.9yrs | €122.00k | 0.058% $ 96.6k | |
| Independent Supervisory Board Member | 6yrs | €100.00k | 0% $ 0 | |
| Supervisory Board Member & Member of Scientific Advisory Board | 4.8yrs | €26.00k | no data | |
| Chief ADAR Scientist & Member of Scientific Advisory Board | 7.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 7yrs | no data | no data | |
| Supervisory Board Member | 2yrs | €77.00k | 0% $ 0 |
7.0yrs
Average Tenure
63.5yo
Average Age
Experienced Board: PRQR's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 05:54 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProQR Therapeutics N.V. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | B. Riley Wealth |
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Steven Seedhouse | Cantor Fitzgerald & Co. |